SK Jang Dong-hyun President "Strengthening Shareholder Returns through SK Biopharm Listing"

[Asia Economy Reporter Park Soyeon] Jang Donghyun, CEO of SK Inc., revealed management performance and long-term corporate value enhancement plans in a shareholder letter on the 9th.

In the letter, CEO Jang stated, "Although uncertainty in the management environment is increasing, we will focus all efforts on maximizing corporate value by building an optimal business portfolio."

He added, "We will also create social value to sustain continuous performance and accelerate shareholder-friendly management by returning management results to shareholders."

He mentioned, "When making investment decisions, we will apply ESG (Environmental, Social Responsibility, Governance) aspects and the level of social value creation as important criteria, and continue to discover impact investments that solve social problems while generating economic value."

Along with this, CEO Jang emphasized, "We will continuously strengthen shareholder returns through the listing of SK Biopharm and optimization of the existing business portfolio."

SK Biopharm, a company developing new drugs related to the central nervous system, passed the preliminary review for listing at the end of last year.

He added, "This year as well, we will maintain dividends at a stable level and implement an active dividend policy by sharing some investment profits with shareholders."

SK Inc. maintained dividends at 5,000 KRW per share last year, the same level as the previous year, and repurchased treasury shares worth 900 billion KRW.

This content was produced with the assistance of AI translation services.